首页|乳腺癌抗人表皮生长因子受体2抗体药物偶联物类药物的耐药机制

乳腺癌抗人表皮生长因子受体2抗体药物偶联物类药物的耐药机制

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
抗体药物偶联物(ADCs)是具有单克隆抗体的精确靶向能力和化疗药物的强效细胞毒性作用的一类抗肿瘤药物。新一代ADCs的问世，给乳腺癌患者带来了生存获益。目前，已有ADCs获批用于人表皮生长因子受体2(HER-2)阳性乳腺癌的治疗，同时还有多种ADCs正在临床试验中。然而，随着ADCs在临床中的应用，耐药问题逐渐出现。文章将对ADCs的作用机制、抗HER-2 ADCs在乳腺癌的疗效概况及耐药机制进行总结。
Drug resistance mechanism of drug conjugates of anti-human epidermal growth factor receptor-2 antibody in breast cancer
Antibody drug conjugates(ADCs)are a class of anti-tumor drugs that combines the precise targeting ability of monoclonal antibodies with the potent cytotoxic effects of chemotherapy drugs.The advent of a new generation of ADCs has brought survival benefits to breast cancer patients.ADCs have been currently approved for treating human epidermal growth factor receptor-2(HER-2)positive breast cancer,and many kinds of ADCs are being evaluated in clinical trials.However,with the increasing use of ADCs in clinical practice,drug resistance issues have gradually emerged.This article summarizes the mechanism of action of ADCs,as well as the efficacy and mechanism of drug resistance of anti-HER-2 ADCs in breast cancer.

Breast neoplasmsAntibody drug conjugatesHuman epidermal growth factor receptor-2Drug resistance

韩兆雪、孙涛、徐君南、李晓睿、马艺文

展开 >

中国医科大学肿瘤医院 大连理工大学附属肿瘤医院 辽宁省肿瘤医院乳腺内一科,沈阳 110042

乳腺肿瘤 抗体药物偶联物 人表皮生长因子受体2 耐药

沈阳市乳腺癌临床医学研究中心课题沈阳市科学技术计划公共卫生研发专项辽宁省肿瘤医院-大连理工大学"医-工交叉研究基金"项目辽宁省肿瘤医院-大连理工大学"医-工交叉研究基金"项目

2020-48-3-122-321-31-04202229202230

2024

10.13455/j.cnki.cjcor.113494-2024-2024-0101

中国肿瘤临床与康复
中国癌症研究基金会

中国肿瘤临床与康复

影响因子：0.887
ISSN：1005-8664
年,卷(期)：2024.31(3)